Analyst Tracker/Brandon Folkes

Brandon Folkes

Q: How accurate are Brandon Folkes's stock ratings?

About 45% of Brandon's ratings were profitable over a one-year hold, with an average return of -2.1% per rating, measured by 13Foresight from historical prices.

Q: How is Brandon ranked?

Brandon Folkes is ranked #2648 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

H.C. Wainwright

Wall Street Analyst

★★☆☆☆

#2648

on 13Foresight · ranked by our own returns

45%

Success Rate

-2.1%

Average Return

30 of 67 calls profitable · -5.6% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 45% of Brandon Folkes's ratings turned a profit when each position was held for 1 year — averaging -2.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

217 Buy 1 Hold 0 Sell

Brandon's Stock Coverage 46 ratings · 2026-08-09

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
XERS Xeris Pharmaceuticals	Aug 07, 2026	BUY	Strong Buy +21.4% avg upside 10 analysts	$10.00 26.15% Upside	·	·
COLL Collegium Pharmaceutical	Aug 07, 2026	BUY	Strong Buy +37.7% avg upside 8 analysts	$60.00 103.61% Upside	+0.0%	·
ZVRA Zevra Therapeutics	Aug 06, 2026	BUY	Strong Buy +89.5% avg upside 15 analysts	$26.00 124.83% Upside	-2.7%	·
MNKD MannKind	Aug 06, 2026	BUY	Buy +71.1% avg upside 22 analysts	$10.00 143.24% Upside	·	·
RNTX Rein Therapeutics	Aug 05, 2026	BUY	Strong Buy +1000.9% avg upside 6 analysts	$8.00 878.62% Upside	+14.6%	·
INDV Indivior	Aug 04, 2026	BUY	Strong Buy -3.6% avg upside 10 analysts	$48.00 23.57% Upside	+5.9%	·
OMER Omeros	Aug 03, 2026	BUY	Buy +57.3% avg upside 14 analysts	$33.00 149.02% Upside	+5.5%	·
TSE:EPRX Eupraxia Pharmaceuticals	Jul 31, 2026	BUY	Strong Buy +136.3% avg upside 9 analysts	$15.35 62.21% Upside	+5.3%	·
PYPD PolyPid	Jul 21, 2026	BUY	Strong Buy +227.6% avg upside 7 analysts	$13.00 168.58% Upside	+29.4%	·
TRVI Trevi Therapeutics	Jul 20, 2026	BUY	Strong Buy +30.3% avg upside 18 analysts	$24.00 29.72% Upside	+10.4%	·
RANI Rani Therapeutics Holdings	Jul 16, 2026	BUY	Strong Buy +1099.5% avg upside 10 analysts	$11.00 1288.96% Upside	+17.9%	·
TSE:CRDL Cardiol Therapeutics	Jul 14, 2026	BUY	Strong Buy +454.7% avg upside 6 analysts	$12.56 531.25% Upside	+22.1%	·
ANIP ANI Pharmaceuticals	Jul 13, 2026	BUY	Strong Buy +31.5% avg upside 11 analysts	$121.00 54.65% Upside	-2.3%	·
CNTB Connect Biopharma Holdings	Jun 25, 2026	BUY	Strong Buy +197.9% avg upside 12 analysts	$7.00 217.50% Upside	+6.5%	·
ACHV Achieve Life Sciences	Jun 23, 2026	BUY	Strong Buy +134.8% avg upside 14 analysts	$12.00 80.36% Upside	+27.1%	·
ENTA Enanta Pharmaceuticals	Jun 23, 2026	BUY	Buy +138.3% avg upside 17 analysts	$20.00 45.15% Upside	-2.1%	·
TRAW Traws Pharma	Jun 18, 2026	HOLD	Buy +5821.1% avg upside 10 analysts	$1.00 88.05% Upside	-37.6%	·
HRTX Heron Therapeutics	Jun 08, 2026	BUY	Strong Buy +5433.0% avg upside 21 analysts	$2.00 307.40% Upside	+9.1%	·
TLPH Talphera	Jun 05, 2026	BUY	Buy +229.6% avg upside 15 analysts	$3.00 109.88% Upside	+83.3%	·
VALN Valneva	May 26, 2026	BUY	Buy +110.7% avg upside 5 analysts	$18.00 239.53% Upside	-12.4%	·
SGMT Sagimet Biosciences, Inc. Class A	May 26, 2026	BUY	Strong Buy +211.3% avg upside 15 analysts	$29.00 220.07% Upside	-1.5%	·
MIST Milestone Pharmaceuticals	May 26, 2026	BUY	Strong Buy +567.5% avg upside 7 analysts	$8.00 555.83% Upside	-14.3%	·
SINT Sintx Technologies	May 20, 2026	BUY	Strong Buy +387.2% avg upside 8 analysts	$10.00 502.47% Upside	-24.9%	·
PTHS Pelthos Therapeutics	May 15, 2026	BUY	Strong Buy +100.1% avg upside 8 analysts	$60.00 111.51% Upside	+6.1%	·
CRMD Cormedix	May 15, 2026	BUY	Strong Buy +101.0% avg upside 13 analysts	$13.00 74.82% Upside	-1.5%	·
DERM Journey Medical Corp	May 14, 2026	BUY	Strong Buy +91.8% avg upside 11 analysts	$13.00 102.12% Upside	+2.8%	·
ADIL Adial Pharmaceuticals	Mar 04, 2025	BUY	Strong Buy +1034.3% avg upside 7 analysts	$200.00 4925.15% Upside	-89.4%	·
RMTI Rockwell Med	Nov 14, 2024	BUY	Hold +122.5% avg upside 11 analysts	$5.00 30.00% Downside	·	·
EBS Emergent Biosolutions	Aug 22, 2024	BUY	Buy +423.4% avg upside 9 analysts	$16.00 230.57% Upside	-2.8%	·
CERS Cerus	May 03, 2024	BUY	Strong Buy +128.7% avg upside 10 analysts	$4.00 70.24% Upside	-16.7%	·
ELUT Elutia	May 12, 2023	BUY	Strong Buy +852.9% avg upside 5 analysts	$10.00 1076.40% Upside	+41.8%	·
OBSEF ObsEva	Mar 17, 2023	HOLD	Buy +10799900.0% avg upside 8 analysts	—	·	·
IMVIF IMV	Mar 17, 2023	HOLD	Buy +325966629.9% avg upside 7 analysts	—	·	·
EGRX Eagle Pharmaceuticals	Mar 13, 2023	HOLD	Strong Sell +49015.9% avg upside 2 analysts	$33.00 64733.07% Upside	·	·
VERU Veru	Feb 09, 2023	BUY	Strong Buy +746.4% avg upside 10 analysts	$15.00 543.80% Upside	-90.4%	·
R Ryder System	Feb 03, 2023	BUY	Strong Buy -10.4% avg upside 15 analysts	$48.00 81.66% Downside	+23.6%	·
RDHL RedHill Biopharma	Nov 22, 2022	BUY	Strong Buy +3205.7% avg upside 7 analysts	$40.00 6511.65% Upside	·	·
SRNE Sorrento Therapeutics	Nov 02, 2022	BUY	Strong Buy +4999900.0% avg upside 7 analysts	$5.00 999900.06% Upside	·	·
TRVN Trevena	Mar 31, 2022	BUY	Buy +1424900.0% avg upside 11 analysts	$50.00 4999900.02% Upside	·	·
ALKS Alkermes	Jan 27, 2022	BUY	Strong Buy -15.5% avg upside 34 analysts	$32.00 34.99% Downside	+18.2%	·
AXGN AxoGen	Nov 04, 2021	BUY	Strong Buy -24.2% avg upside 21 analysts	$25.00 46.21% Downside	-16.6%	·
JAZZ Jazz Pharmaceuticals	Oct 06, 2021	BUY	Strong Buy -7.8% avg upside 35 analysts	$210.00 18.21% Downside	+1.6%	·
VRAYQ Viewray	Aug 09, 2021	BUY	Strong Buy +558333233.3% avg upside 12 analysts	$8.00 799999899.91% Upside	·	·
SMTI Sanara MedTech	Jun 30, 2021	BUY	Buy +15.0% avg upside 5 analysts	$45.00 32.03% Upside	-43.5%	·
SIBN SI-Bone	Dec 15, 2020	BUY	Strong Buy +39.4% avg upside 18 analysts	$33.00 77.25% Upside	-27.2%	·
PAHC Phibro Animal Health	Sep 12, 2016	BUY	Sell +8.3% avg upside 10 analysts	$30.00 12.50% Downside	+39.8%	·

🔒 41 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Brandon Folkes — Frequently Asked Questions

How accurate are Brandon Folkes's stock ratings?

Based on the calls 13Foresight could measure, about 45% of Brandon's ratings were profitable over a one-year hold, with an average return of -2.1% per rating, or -5.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Brandon ranked on 13Foresight?

Brandon Folkes is currently ranked #2648 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Brandon cover?

Brandon most recently has ratings on XERS, COLL, ZVRA, MNKD, RNTX, INDV, OMER, TSE:EPRX, PYPD, TRVI, RANI, TSE:CRDL and 34 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Brandon Folkes

Rating Distribution

Welcome to 13Foresight!